創勝集團-B(06628.HK):於2025年ASCO年度大會首次公佈 Osemitamab(TST001)三聯療法治療一線胃或胃食管結合部腺癌的中位生存期新數據的最新業務進展
格隆匯6月2日丨創勝集團-B(06628.HK)公佈,Osemitamab (TST001)聯合納武利尤單抗和CAPOX作爲晚期胃或胃食管結合部腺癌(TranStar102)一線治療的一項正在進行的II期臨牀試驗G隊列更新研究數據。該研究結果以壁報形式(摘要編號:#4032) 亮相於再美國伊利諾伊州芝加哥市舉行的2025年美國臨牀腫瘤學會年會(ASCO 2025)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.